This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Renal disease				
Renal damage	Sirtuin 1 (SIRT1)	<p><i>In vitro</i> and mouse studies suggest that SIRT1 activation could help treat renal damage associated with oxidative stress. In mouse renal medullary interstitial cells exposed to oxidative stress, Sirt1 activators prevented apoptosis compared with no treatment. In a mouse model of kidney injury associated with oxidative stress, Sirt1 activators reduced renal medulla apoptosis and fibrosis compared with vehicle control. Next steps could include testing SIRT1 activation in additional animal models of renal damage.</p> <p>Elixir Pharmaceuticals Inc. has SIRT1 activators in preclinical development to treat cancer and metabolic diseases.</p> <p>GlaxoSmithKline plc has SIRT1 activators including GSK184072 and GSK2245840 in preclinical and clinical testing to treat metabolic diseases and other disorders.</p> <p>SciBX 3(15); doi:10.1038/scibx.2010.475 Published online April 15, 2010</p>	Patent and licensing status unavailable	<p>He, W. <i>et al. J. Clin. Invest.</i>; published online March 24, 2010; doi:10.1172/JCI41563</p> <p>Contact: Chuan-Ming Hao, Vanderbilt University Medical Center, Nashville, Tenn. e-mail: chuanming.hao@vanderbilt.edu</p>